Low-dose abdominal radiation as a docetaxel chemosensitizer for recurrent epithelial ovarian cancer

A phase i study of the Gynecologic Oncology Group

Charles A. Kunos, Michael W. Sill, Thomas E. Buekers, Joan L. Walker, Jeanne Schilder, S. Diane Yamada, Steven E. Waggoner, Mohammed Mohiuddin, Paula M. Fracasso

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

Objectives: The aim of this study was to determine the maximum tolerated dose and dose-limiting toxicity (DLT) of whole abdomen radiation as a chemosensitizer of weekly docetaxel for women with recurrent epithelial ovarian fallopian tube, or peritoneal cancers. Patients and methods: Women were enrolled on one of three dose levels of docetaxel (20, 25, or 30 mg/m2) administered weekly with concurrent low-dose whole abdominal radiation given as 60 cGy bid 2 days weekly for a total of 6 weeks. Results: Thirteen women were enrolled and received 70 weekly treatments of docetaxel in combination with radiation therapy. At the first dose level, docetaxel 25 mg/m2, grade 3 fatigue and thrombocytopenia were observed. At the next dose level, docetaxel 30 mg/m2, grade 3 febrile neutropenia, grade 4 thrombocytopenia with epistaxis, and grade 3 diarrhea were observed. Given these dose-limiting toxicities, a lower dose of docetaxel 20 mg/m2 was administered and found to be tolerable. No objective responses were observed among the 10 patients with measurable disease; however, the median progression-free survival (PFS) in all patients was 3.3 months, and 3 of the patients with measurable disease were free of tumor progression after 6 months (30%; 90% confidence interval 8.7-61%). Conclusions: Twice weekly low-dose whole abdomen radiation during weekly docetaxel 20 mg/m2 was well-tolerated. Given the PFS demonstrated in these women with resistant ovarian cancer, further study of whole abdominal radiation and concurrent chemotherapy may be warranted.

Original languageEnglish
Pages (from-to)224-228
Number of pages5
JournalGynecologic Oncology
Volume120
Issue number2
DOIs
StatePublished - Feb 2011

Fingerprint

docetaxel
Radiation
Abdomen
Disease-Free Survival
Febrile Neutropenia
Epistaxis
Maximum Tolerated Dose
Fallopian Tubes
Ovarian epithelial cancer
Ovarian Neoplasms
Fatigue
Diarrhea
Neoplasms
Radiotherapy

Keywords

  • Abdominal radiation
  • Chemosensitizer
  • Docetaxel
  • Ovarian cancer

ASJC Scopus subject areas

  • Obstetrics and Gynecology
  • Oncology

Cite this

Low-dose abdominal radiation as a docetaxel chemosensitizer for recurrent epithelial ovarian cancer : A phase i study of the Gynecologic Oncology Group. / Kunos, Charles A.; Sill, Michael W.; Buekers, Thomas E.; Walker, Joan L.; Schilder, Jeanne; Yamada, S. Diane; Waggoner, Steven E.; Mohiuddin, Mohammed; Fracasso, Paula M.

In: Gynecologic Oncology, Vol. 120, No. 2, 02.2011, p. 224-228.

Research output: Contribution to journalArticle

Kunos, Charles A. ; Sill, Michael W. ; Buekers, Thomas E. ; Walker, Joan L. ; Schilder, Jeanne ; Yamada, S. Diane ; Waggoner, Steven E. ; Mohiuddin, Mohammed ; Fracasso, Paula M. / Low-dose abdominal radiation as a docetaxel chemosensitizer for recurrent epithelial ovarian cancer : A phase i study of the Gynecologic Oncology Group. In: Gynecologic Oncology. 2011 ; Vol. 120, No. 2. pp. 224-228.
@article{0c06496f7f84437ca1699e5380dbe584,
title = "Low-dose abdominal radiation as a docetaxel chemosensitizer for recurrent epithelial ovarian cancer: A phase i study of the Gynecologic Oncology Group",
abstract = "Objectives: The aim of this study was to determine the maximum tolerated dose and dose-limiting toxicity (DLT) of whole abdomen radiation as a chemosensitizer of weekly docetaxel for women with recurrent epithelial ovarian fallopian tube, or peritoneal cancers. Patients and methods: Women were enrolled on one of three dose levels of docetaxel (20, 25, or 30 mg/m2) administered weekly with concurrent low-dose whole abdominal radiation given as 60 cGy bid 2 days weekly for a total of 6 weeks. Results: Thirteen women were enrolled and received 70 weekly treatments of docetaxel in combination with radiation therapy. At the first dose level, docetaxel 25 mg/m2, grade 3 fatigue and thrombocytopenia were observed. At the next dose level, docetaxel 30 mg/m2, grade 3 febrile neutropenia, grade 4 thrombocytopenia with epistaxis, and grade 3 diarrhea were observed. Given these dose-limiting toxicities, a lower dose of docetaxel 20 mg/m2 was administered and found to be tolerable. No objective responses were observed among the 10 patients with measurable disease; however, the median progression-free survival (PFS) in all patients was 3.3 months, and 3 of the patients with measurable disease were free of tumor progression after 6 months (30{\%}; 90{\%} confidence interval 8.7-61{\%}). Conclusions: Twice weekly low-dose whole abdomen radiation during weekly docetaxel 20 mg/m2 was well-tolerated. Given the PFS demonstrated in these women with resistant ovarian cancer, further study of whole abdominal radiation and concurrent chemotherapy may be warranted.",
keywords = "Abdominal radiation, Chemosensitizer, Docetaxel, Ovarian cancer",
author = "Kunos, {Charles A.} and Sill, {Michael W.} and Buekers, {Thomas E.} and Walker, {Joan L.} and Jeanne Schilder and Yamada, {S. Diane} and Waggoner, {Steven E.} and Mohammed Mohiuddin and Fracasso, {Paula M.}",
year = "2011",
month = "2",
doi = "10.1016/j.ygyno.2010.10.018",
language = "English",
volume = "120",
pages = "224--228",
journal = "Gynecologic Oncology",
issn = "0090-8258",
publisher = "Academic Press Inc.",
number = "2",

}

TY - JOUR

T1 - Low-dose abdominal radiation as a docetaxel chemosensitizer for recurrent epithelial ovarian cancer

T2 - A phase i study of the Gynecologic Oncology Group

AU - Kunos, Charles A.

AU - Sill, Michael W.

AU - Buekers, Thomas E.

AU - Walker, Joan L.

AU - Schilder, Jeanne

AU - Yamada, S. Diane

AU - Waggoner, Steven E.

AU - Mohiuddin, Mohammed

AU - Fracasso, Paula M.

PY - 2011/2

Y1 - 2011/2

N2 - Objectives: The aim of this study was to determine the maximum tolerated dose and dose-limiting toxicity (DLT) of whole abdomen radiation as a chemosensitizer of weekly docetaxel for women with recurrent epithelial ovarian fallopian tube, or peritoneal cancers. Patients and methods: Women were enrolled on one of three dose levels of docetaxel (20, 25, or 30 mg/m2) administered weekly with concurrent low-dose whole abdominal radiation given as 60 cGy bid 2 days weekly for a total of 6 weeks. Results: Thirteen women were enrolled and received 70 weekly treatments of docetaxel in combination with radiation therapy. At the first dose level, docetaxel 25 mg/m2, grade 3 fatigue and thrombocytopenia were observed. At the next dose level, docetaxel 30 mg/m2, grade 3 febrile neutropenia, grade 4 thrombocytopenia with epistaxis, and grade 3 diarrhea were observed. Given these dose-limiting toxicities, a lower dose of docetaxel 20 mg/m2 was administered and found to be tolerable. No objective responses were observed among the 10 patients with measurable disease; however, the median progression-free survival (PFS) in all patients was 3.3 months, and 3 of the patients with measurable disease were free of tumor progression after 6 months (30%; 90% confidence interval 8.7-61%). Conclusions: Twice weekly low-dose whole abdomen radiation during weekly docetaxel 20 mg/m2 was well-tolerated. Given the PFS demonstrated in these women with resistant ovarian cancer, further study of whole abdominal radiation and concurrent chemotherapy may be warranted.

AB - Objectives: The aim of this study was to determine the maximum tolerated dose and dose-limiting toxicity (DLT) of whole abdomen radiation as a chemosensitizer of weekly docetaxel for women with recurrent epithelial ovarian fallopian tube, or peritoneal cancers. Patients and methods: Women were enrolled on one of three dose levels of docetaxel (20, 25, or 30 mg/m2) administered weekly with concurrent low-dose whole abdominal radiation given as 60 cGy bid 2 days weekly for a total of 6 weeks. Results: Thirteen women were enrolled and received 70 weekly treatments of docetaxel in combination with radiation therapy. At the first dose level, docetaxel 25 mg/m2, grade 3 fatigue and thrombocytopenia were observed. At the next dose level, docetaxel 30 mg/m2, grade 3 febrile neutropenia, grade 4 thrombocytopenia with epistaxis, and grade 3 diarrhea were observed. Given these dose-limiting toxicities, a lower dose of docetaxel 20 mg/m2 was administered and found to be tolerable. No objective responses were observed among the 10 patients with measurable disease; however, the median progression-free survival (PFS) in all patients was 3.3 months, and 3 of the patients with measurable disease were free of tumor progression after 6 months (30%; 90% confidence interval 8.7-61%). Conclusions: Twice weekly low-dose whole abdomen radiation during weekly docetaxel 20 mg/m2 was well-tolerated. Given the PFS demonstrated in these women with resistant ovarian cancer, further study of whole abdominal radiation and concurrent chemotherapy may be warranted.

KW - Abdominal radiation

KW - Chemosensitizer

KW - Docetaxel

KW - Ovarian cancer

UR - http://www.scopus.com/inward/record.url?scp=79251599499&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79251599499&partnerID=8YFLogxK

U2 - 10.1016/j.ygyno.2010.10.018

DO - 10.1016/j.ygyno.2010.10.018

M3 - Article

VL - 120

SP - 224

EP - 228

JO - Gynecologic Oncology

JF - Gynecologic Oncology

SN - 0090-8258

IS - 2

ER -